ANI Pharmaceuticals’ second quarter was marked by strong year-on-year growth in its rare disease and generics businesses, but the market reacted negatively to the results. Management highlighted the rapid scale-up of its sales force for Cortrophin Gel and robust demand across existing specialties. CEO Nikhil Lalwani noted, “We are seeing significant momentum in demand in the third quarter with July representing the highest month for new cases initiated,” attributing quarterly performance to pers

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ANI Pharmaceuticals (NASDAQ:ANIP) and the best and worst performers in the generic pharmaceuticals industry.

ANI Pharmaceuticals' low valuation and strong 2026 growth outlook face a key test as Cortrophin execution risk rises.

Cortrophin guidance cuts put more pressure on ANI Pharmaceuticals' second-half execution as the drug must deliver a sharper growth ramp.

Rare disease revenue surged 43.5% as Cortrophin Gel sales accelerated across key specialties.

Specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 25.9% year on year to $266 million. On the other hand, the company’s full-year revenue guidance of $1.11 billion at the midpoint came in 1% below analysts’ estimates. Its non-GAAP profit of $2.21 per share was 8.2% above analysts’ consensus estimates.

ANI Pharmaceuticals tops Q2 earnings and sales estimates, but shares fall as the company cuts its 2026 Cortrophin Gel revenue outlook.

ANI Pharmaceuticals earnings beat and guidance reset ANI Pharmaceuticals (ANIP) reported better than expected Q2 2026 results and reaffirmed full year revenue guidance, while trimming its Cortrophin Gel outlook, a mix that appears to have driven recent stock volatility. See our latest analysis for ANI Pharmaceuticals. Despite the strong Q2 update, ANI Pharmaceuticals' share price fell 5.3% over the past day and is down 7.7% over the past month. However, the 5 year total shareholder return of...

Moby summary of ANI Pharmaceuticals, Inc.'s Q2 2026 earnings call

ANI Pharmaceuticals Inc (ANIP) posts record Q2 2026 results with 26% revenue growth, driven by strong Cortrophin Gel performance and successful gout expansion initiatives.

ANI Pharmaceuticals (NASDAQ:ANIP) reported record second-quarter revenue and adjusted EBITDA as growth in its Cortrophin Gel rare-disease franchise and generics business lifted results, while the company modestly reduced its full-year Cortrophin revenue outlook to reflect first-half performance. To

ANI Pharmaceuticals Inc. (NASDAQ:ANIP) reported stronger-than-expected second-quarter results on Friday, but shares fell in pre-market trading after the company lowered its sales forecast for its flagship Cortrophin Gel treatment.

While the top- and bottom-line numbers for ANI (ANIP) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

ANI (ANIP) delivered earnings and revenue surprises of +9.95% and +1.26%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 25.9% year on year to $266 million. On the other hand, the company’s full-year revenue guidance of $1.11 billion at the midpoint came in 1% below analysts’ estimates. Its non-GAAP profit of $2.21 per share was 8.2% above analysts’ consensus estimates.

Denali Therapeutics (DNLI) delivered earnings and revenue surprises of +5.56% and +143.35%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

ABCELLERA BIOLG (ABCL) delivered earnings and revenue surprises of -5.88% and -46.73%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Ovid Therapeutics (OVID) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have not only realized strong financial performance but also propelled the broader industry’s returns as healthcare stocks have gained 16.6% over the past six months while the S&P 500 was up 7.1%.

TG Therapeutics (TGTX) delivered earnings and revenue surprises of -87.81% and +4.08%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

ANI (ANIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Moderna (MRNA) delivered earnings and revenue surprises of 0.00% and +14.49%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

ANI Pharmaceuticals recently reported positive topline results from its Phase 4 SYNCHRONICITY trial of the Fluocinolone Acetonide Intravitreal Implant for chronic non-infectious uveitis affecting the posterior segment, with both 6‑month co-primary endpoints in visual acuity and retinal thickness met in 108 U.S. patients. The data help reinforce the expanded ILUVIEN label for chronic NIU-PS by showing clinically meaningful inflammatory control in a real-world, predominantly older patient...

Ani Pharmaceuticals (ANIP) stock was recently in focus after the company reported statistically significant topline results from its Phase 4 SYNCHRONICITY trial of a fluocinolone acetonide intravitreal implant for chronic non infectious posterior segment uveitis. See our latest analysis for ANI Pharmaceuticals. Despite the positive SYNCHRONICITY data, ANI Pharmaceuticals’ recent share price return has been soft, with the stock down 6.13% over the past month and 1.96% over the past week...

Since January 2026, ANI Pharmaceuticals has been in a holding pattern, posting a small loss of 3.5% while floating around $78.49. The stock also fell short of the S&P 500’s 7.9% gain during that period.

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 9.7% over the past six months, topping the S&P 500 by 1.8 percentage points.

Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside risk because they lack the scale and staying power of their larger competitors.